HMGCR and heavy chain disease: Compared to the HCD group, the 5-uRCK and ellagic acid treatment groups had significantly increased expression of AMPK, p-AMPK, p-HMGCR, and INSIG-1 in a dose-dependent manner and decreased expression of HMGCR and mSREBP-2.